| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10594292 | Bioorganic & Medicinal Chemistry Letters | 2012 | 5 Pages |
Abstract
The discovery of potent small molecule dual antagonists of the human CCR3 and H1 receptors is described for the treatment of allergic diseases, for example, asthma and allergic rhinitis. Optimizing in vitro potency and metabolic stability, starting from a CCR1 lead compound, led to compound 20 with potent dual CCR3/H1 activity and in vitro metabolic stability.
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Mark Furber, Lilian Alcaraz, Christopher Luckhurst, Ash Bahl, Haydn Beaton, Keith Bowers, John Collington, Rebecca Denton, David Donald, Elizabeth Kinchin, Cathy MacDonald, Aaron Rigby, Rob Riley, Matt Soars, Brian Springthorpe, Peter Webborn,